港股異動 | 影視娛樂股拉昇 貓眼娛樂大漲近10% 阿里影業升近4%
格隆匯2月3日丨港股影視娛樂股大幅拉昇,貓眼娛樂大漲近10%,稻草熊娛樂漲超9%,歡喜傳媒、阿里影業均升近4%。據電影票房數據分析平台貓眼專業版顯示,截至2日上午9:00左右,春節檔電影預售總票房已達2.11億元,其中《唐人街探案3》以1.52億元位列榜首,佔2021年春節檔總預售的72%左右。預售票房位列第二第三的的分別是《你好,李煥英》和《刺殺小説家》。據瞭解,今年以來內地電影市場逐漸回暖,數據顯示2021年元旦檔期(1月1日-3日)電影票房錄得超過12.98億元,元旦觀影人次超過3,200萬人,其中元旦當日票房逾6億元,刷新中國影史歷年元旦單日最高票房紀錄。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.